Association of LIN28B polymorphisms with chronic hepatitis B virus infection

Qunying Han†, Jiao Sang†, Xiude Fan†, Xiaoyun Wang†, Lu Zeng†, Xiaoge Zhang†, Kun Zhang†, Na Li†, Yi Lv,3 and Zhengwen Liu1,3*

Abstract

Background: LIN28B is involved in multiple cellular developmental processes, tissue inflammatory response and tumourigenesis. The association of LIN28B polymorphisms with hepatitis B virus (HBV) infection remains unknown.

Methods: This study investigated the association of LIN28B rs314277, rs314280, rs369065 and rs7759938 polymorphisms in patients with chronic HBV infection, a major cause of liver disease including hepatocellular carcinoma (HCC). A total of 781 individuals including 515 cases of chronic HBV infection (91 asymptomatic carrier status, 128 chronic hepatitis, 127 cirrhosis and 169 HCC), 97 HBV infection resolvers and 169 healthy controls were investigated.

Results: LIN28 rs314280 genotypes GA + AA were higher in resolver and controls than patients (P = 0.011). Patients had significantly lower rs314280 allele A than resolvers (P = 0.031, OR 0.689, 95%CI 0.491–0.969) or controls (P = 0.034, OR 0.741, 95%CI 0.561–0.978). In dominant model, patients had significantly lower rs314280 genotypes AA+GA than controls (P = 0.008, OR 0.623, 95%CI 0.439–0.884). LIN28 rs7759938 genotypes TC + CC were higher in resolvers and controls than patients (P = 0.015). Patients had significantly lower rs7759938 allele C than resolvers (P = 0.048, OR 0.708, 95%CI 0.503–0.999). In dominant model, patients had significantly lower rs7759938 genotypes TC + CC than controls (P = 0.010, OR 0.632, 95%CI 0.445–0.897). Chronic hepatitis patients had lower frequency of rs369065 genotype TC than asymptomatic carriers, cirrhosis and HCC (P = 0.019).

Conclusions: These results suggest that LIN28B rs314280 and rs7759938 may be related to the susceptibility of chronic HBV infection. Further studies are warranted to examine the association of LIN28B polymorphisms with HBV-related diseases, especially HCC.

Keywords: Chronic hepatitis B virus infection, Hepatocellular carcinoma, Gene polymorphisms, LIN28B
Background
RNA-binding protein lin28 was initially identified as a regulator of developmental timing in Caenorhabditis elegans [1]. Subsequent studies revealed that in mammalian embryonic stem cells, LIN28A proteins regulate the self-renewal through suppression of let-7 microRNAs (miRNAs) and influence of mRNA translation. LIN28A proteins also play important roles in many other biological processes [2–4]. Studies have indicated that LIN28 links inflammation to cell transformation and cancer [5, 6]. There are two homologous LIN28 proteins in mammals: LIN28A and LIN28B, that play crucial roles in diverse cellular developmental processes, tissue inflammatory response and tumorigenesis [5, 7–9]. Different from LIN28A, LIN28B acts solely in the nucleus by sequestrating primary let-7 transcripts and suppressing their processing [9]. LIN28B is more wide-rangingly expressed in various tissues and highly expressed in placenta, fetal liver and testis [10]. LIN28B may be overexpressed in some tumors such as colon cancer [9, 11]. LIN28B enhances cell migration, invasion and metastasis in some cancers such as prostate cancer [12] and colon cancer [13]. LIN28B is associated with aggressive subtypes in certain cancers including high-grade serous ovarian cancers [14], esophageal cancer [15] and colon cancer [9, 13]. LIN28B overexpression is related to reduced patient survival and increased probability of tumor recurrence in colon cancers [16].

In terms of hepatitis B virus (HBV), a major cause of liver disease including hepatocellular carcinoma (HCC) worldwide, LIN28B is involved in the regulation of HBV replication and plays an oncogenic role in HCC. Studies have demonstrated that LIN28B is involved in miRNA-125b-5p mediated post-transcriptional regulation of HBV replication [17]. LIN28B over-expression mediates the suppression of let-7 expression by HBV X protein (HBx) in HepG2 hepatoma cells [18–20]. LIN28B serves as a key driver gene in HBx-induced hepatocarcinogenesis [21]. LIN28B is overexpressed in HCC [10, 18, 22] and its expression promotes transformation and invasion of HCC [18] while the suppression of LIN28B expression inhibits HCC cell proliferation and metastasis [23]. Higher expression of LIN28B is associated with shorter overall survival in HCC patients [22]. LIN28B in the peripheral blood mononuclear cells is shown to be an oncogenic circulating cancer stem cell-like marker associated with recurrence of HCC [24].

The relationship of LIN28B polymorphisms to cancer development, progression and metastasis, and patient prognosis, has also been investigated in some cancers. For example, the LIN28B rs314277 polymorphism was shown to have a significant association with risk of recurrence in patients with stage II colorectal cancer [25]. Although LIN28B has been demonstrated to be involved in HBV replication [17], HBV-related hepatocarcinogenesis [18–21] and the migration, invasion, metastasis and prognosis in HCC [18, 22, 24], the association of LIN28B polymorphisms with the susceptibility of chronic HBV infection and the clinical disease of chronic HBV infection including the development of HCC remains unknown. Therefore, this study investigated the relationship between LIN28B polymorphisms and the susceptibility of chronic HBV infection and HBV-related liver disease including HCC in Han Chinese population.

Methods
Study populations
In total, 515 patients with chronic HBV infection, 97 individuals with spontaneously resolved HBV infection and 169 healthy control individuals from the First Affiliated Hospital of Xi’an Jiaotong University were included in this study. Patients with chronic HBV infection were those who had HBsAg positivity for more than 6 months. Patients infected with other hepatitis viruses (hepatitis A, C, D and E), patients with severe heart, lung, brain, kidney and other important organ diseases which were not related to HBV infection, patients with other liver disease such as alcoholic liver disease, non-alcoholic fatty liver disease, drug-induced liver injury and autoimmune liver disease and patients under 18 years of age were excluded. HBV infection resolvers were individuals who spontaneously resolved from HBV infection with normal liver function, HBsAb and HBcAb positivity, and undetectable HBV DNA. The healthy control individuals were healthy blood donors or those who had normal results of regular physical examination. All subjects were unrelated Han Chinese. All subjects signed informed consent and volunteered to participate in the study. The study was performed in accordance with the Declaration of Helsinki and the study was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University.

Genotyping of the polymorphisms
In the dbSNP database and Hapmap database of NCBI, LIN28B SNPs with minor allele frequency > 0.03 and r² > 0.8 (rs314277, rs314280, rs369065, and rs7759938) were selected for genotyping. Venous blood was collected from all subjects in the morning after overnight fasting. About 2 ml of whole blood was collected in a tube containing EDTA anticoagulant and stored below −30°C.

Genomic DNA was extracted using TIANGEN blood genomic DNA extraction kit following the instructions of the manufacturer (Beijing Tiangen Biochemical Technology Co., Ltd., Beijing, China). The genotyping of the polymorphisms was performed using genomic DNA by the propriety multiplex SNP genotyping system SNPsCan
Patients, patients with chronic HBV infection; resolvers, HBV infection resolvers; controls, Healthy controls. The t-test or Chi-squared test was used for comparison diacstic of the patients with HBV infection

Gender and age in patients with chronic HBV infection, HBV infection resolvers and healthy controls and the clinical Table 1

|                         | Patients (n = 515) | Resolvers (n = 97) | Controls (n = 169) | P                  |
|-------------------------|-------------------|-------------------|-------------------|--------------------|
| Gender (male/female)    | 360/155           | 65/32             | 105/64            | 0.168              |
| Age [mean (range) years]| 41.87 ± 13.30 (18–78) | 40.04 ± 13.22 (28–72) | 43.38 ± 13.25 (24–76) | 0.136              |
| Clinical diagnosis      |                   |                   |                   |                    |
| Asymptomatic carrier status | 91                |                   |                   |                    |
| Chronic hepatitis       | 128               |                   |                   |                    |
| Cirrhosis               | 127               |                   |                   |                    |
| Hepatocellular carcinoma| 169               |                   |                   |                    |

Patients, patients with chronic HBV infection; resolvers, HBV infection resolvers; controls, Healthy controls. The t-test or Chi-squared test was used for comparison
had no significant difference between patients with chronic HBV infection, HBV infection resolvers and healthy controls ($P = 0.356$, Table S4). The frequency of rs7759938 allele C was higher in resolvers and healthy controls than in patients ($P = 0.043$, Table S4).

**Genotype and allele frequencies between patients with chronic HBV infection, HBV infection resolvers and healthy controls in different genetic models**

The genotype and allele frequencies of rs314277 and rs369065 between patients with chronic HBV infection, HBV infection resolvers and healthy controls had no significant difference in any genetic models (Table S5, Table S6).

For genotype and allele frequencies of rs314280, patients with chronic HBV infection had significantly lower allele A than resolvers ($P = 0.031$, OR 0.689, 95%CI 0.491–0.969) or controls ($P = 0.034$, OR 0.741, 95%CI 0.561–0.978, Table 2). In codominant and overdominant model, patients had significantly lower genotype GA than controls ($P = 0.005$, $P_c = 0.010$, OR 0.593, 95%CI 0.413–0.853 and $P = 0.005$, OR 0.603, 95%CI 0.423–0.859, respectively). In dominant model, patients had significantly lower genotypes AA+ GA than controls ($P = 0.008$, OR 0.705, 95%CI 0.507–0.981) or controls ($P = 0.036$, OR 0.744, 95%CI 0.564–0.981, Table 2). No significant difference was observed between controls and resolvers in rs314280 genotype and allele frequencies (Table 2).

For genotype and allele frequencies of rs7759938, patients with chronic HBV infection had significantly lower allele C than resolvers ($P = 0.048$, OR 0.708, 95%CI 0.503–0.999, Table 3). In codominant and overdominant model, patients had significantly lower genotype TC than controls ($P = 0.005$, $P_c = 0.01$, OR 0.593, 95%CI 0.413–0.853 and $P = 0.004$, OR 0.594, 95%CI 0.418–0.850, respectively, Table 3). In dominant model, patients had significantly lower genotypes TC+ CC than controls ($P = 0.010$, OR 0.632, 95%CI 0.445–0.897, Table 3).

### Table 2 LIN28B rs314280 genotype and allele frequencies in patients with chronic HBV infection, HBV infection resolvers and healthy controls

| Genotype | Patients (n = 515) | Resolvers (n = 97) | Controls (n = 169) | Patients vs. resolvers | Patients vs. controls | Resolvers vs. controls |
|----------|-------------------|-------------------|-------------------|------------------------|----------------------|-----------------------|
|          |                    |                    |                   | $P$                     | OR (95%CI)           | $P$                   | OR (95%CI)           | $P$                   | OR (95%CI)           |
| Codominant | GG (60.8)         | 313 (60.8)         | 49 (50.5)         | 83 (49.1)              | Reference            | Reference             | Reference            | Reference            |
|          | GA (33.0)         | 170 (33.0)         | 38 (39.2)         | 76 (45.0)              | 0.130                | 0.700 (0.441–1.113)   | 0.005*               | 0.593 (0.413–0.853)   | 0.535                 | 0.847 (0.501–1.433)   |
|          | AA (6.2)          | 32 (6.2)           | 10 (10.3)         | 10 (5.9)               | 0.074                | 0.501 (0.232–1.083)   | 0.668                | 1.178 (0.401–1.797)   | 0.271                 | 1.694 (0.658–4.358)   |
| Dominant | GG (60.8)         | 313 (60.8)         | 49 (50.5)         | 83 (49.1)              | Reference            | Reference             | Reference            | Reference            |
|          | AA+GA (39.2)      | 202 (39.2)         | 48 (49.5)         | 86 (50.9)              | 0.059                | 0.659 (0.426–1.018)   | 0.008                | 0.623 (0.439–0.884)   | 0.826                 | 0.945 (0.574–1.558)   |
|          | AA (6.2)          | 32 (6.2)           | 10 (10.3)         | 10 (5.9)               | 0.148                | 0.576 (0.273–1.215)   | 0.889                | 1.053 (0.506–2.191)   | 0.196                 | 1.828 (0.732–4.562)   |
| Recessive | GG+GA (93.8)      | 483 (93.8)         | 87 (89.7)         | 159 (94.1)             | Reference            | Reference             | Reference            | Reference            |
|          | AA (6.2)          | 32 (6.2)           | 10 (10.3)         | 10 (5.9)               | 0.148                | 0.576 (0.273–1.215)   | 0.889                | 1.053 (0.506–2.191)   | 0.196                 | 1.828 (0.732–4.562)   |
| Overdominant | GG+AA (67.0)     | 345 (67.0)         | 59 (60.8)         | 93 (55.0)              | Reference            | Reference             | Reference            | Reference            |
|          | GA (33.0)         | 170 (33.0)         | 38 (39.2)         | 76 (45.0)              | 0.240                | 0.765 (0.489–1.196)   | 0.005                | 0.603 (0.423–0.859)   | 0.358                 | 0.788 (0.474–1.310)   |
|          | –                 | –                  | –                 | –                     | 0.038                | 0.705 (0.507–0.981)   | 0.036                | 0.744 (0.564–0.981)   | 0.709                 | 0.927 (0.624–1.378)   |

| Allele  | Patients (n = 515) | Resolvers (n = 97) | Controls (n = 169) | Patients vs. resolvers | Patients vs. controls | Resolvers vs. controls |
|---------|--------------------|--------------------|--------------------|------------------------|----------------------|-----------------------|
| G (77.3)| 796 (77.3)         | 136 (70.1)         | 242 (71.6)         | Reference              | Reference            | Reference             | Reference            |
| A (22.7)| 234 (22.7)         | 58 (29.9)          | 96 (28.4)          | 0.031                  | 0.689 (0.491–0.969)   | 0.034                | 0.741 (0.561–0.978)   | 0.714                 | 1.075 (0.730–1.584)   |

Data are presented as n (%). * $P_c$ (P value by Bonferroni correction) = 0.010. Genotypic association tests between groups assuming codominant, dominant or log-additive genetic models were carried out by univariate logistic regression using SNPstats and odds ratios (OR) with 95% confidence interval (CI) were calculated. Multiple testing correction was performed by the Bonferroni method.
In additive model, the genotype frequencies of rs7759938 were significantly different between patients and controls ($P=0.033$, OR 0.741, 95%CI 0.562–0.977, Table 3). No significant difference was observed between controls and resolver in rs7759938 genotype and allele frequencies (Table 3).

Haplotype frequencies in patients with chronic HBV infection, HBV infection resolvers and healthy controls

The four SNPs of the LIN28B gene constitute 12 haplotypes. The 4 haplotypes with a frequency greater than 0.03 were analyzed. The results show that the 4 haplotype frequencies between patients with chronic HBV infection, HBV infection resolvers and healthy controls had no significant difference but patients had a tendency of lower frequency of rs314277-rs314280-rs369065-rs7759938 haplotype C-A-C-C than resolver ($P=0.053$) or controls ($P=0.069$, Table S7).

**Table 3** LIN28B rs7759938 genotype and allele frequencies in patients with chronic HBV infection, HBV infection resolvers and healthy controls

| Genotype | Patients (n = 515) | Resolvers (n = 97) | Controls (n = 169) | Patients vs. resolvers | Patients vs. controls | Resolvers vs. controls |
|----------|-------------------|-------------------|-------------------|------------------------|----------------------|-----------------------|
|          | Patients vs. resolvers | Patients vs. controls | Resolvers vs. controls |
|          | P | OR | 95%CI | P | OR | 95%CI | P | OR | 95%CI |
| Co-dominant | TT | 317 (61.6) | 50 (51.5) | 85 (50.3) | Reference | Reference | Reference |
|         | TC | 166 (32.2) | 38 (39.2) | 75 (44.4) | 0.113 | 0.689 (0.434–1.099) | 0.005* | 0.593 (0.413–0.853) | 0.576 | 0.861 (0.510–1.454) |
|         | CC | 32 (6.2) | 9 (9.3) | 9 (5.3) | 0.150 | 0.561 (0.253–1.245) | 0.904 | 0.953 (0.438–2.074) | 0.289 | 1.700 (0.633–4.563) |
| Dominant | TT | 317 (61.6) | 50 (51.5) | 85 (50.3) | Reference | Reference | Reference |
|         | TC + CC | 198 (38.4) | 47 (48.5) | 84 (49.7) | 0.065 | 0.664 (0.430–1.028) | 0.010 | 0.632 (0.445–0.897) | 0.844 | 0.951 (0.577–1.567) |
| Recessive | TT + TC | 483 (93.8) | 88 (90.7) | 160 (94.7) | Reference | Reference | Reference |
|         | CC | 32 (6.2) | 9 (9.3) | 9 (5.3) | 0.271 | 0.648 (0.299–1.404) | 0.673 | 1.178 (0.550–2.521) | 0.222 | 1.818 (0.696–4.748) |
| Over-dominant | TT + CC | 349 (67.8) | 59 (60.8) | 94 (55.6) | Reference | Reference | Reference |
|         | TC | 166 (32.2) | 38 (39.2) | 75 (44.4) | 0.184 | 0.739 (0.472–1.155) | 0.004 | 0.594 (0.418–0.850) | 0.409 | 0.807 (0.486–1.342) |
| Additive | – | – | – | – | 0.058 | 0.725 (0.520–1.010) | 0.033 | 0.741 (0.562–0.977) | 0.848 | 0.962 (0.645–1.435) |
| Allele | T | 800 (77.7) | 138 (71.1) | 245 (72.5) | Reference | Reference | Reference |
|         | C | 230 (22.3) | 56 (28.9) | 93 (27.5) | 0.048 | 0.708 (0.503–0.999) | 0.051 | 0.757 (0.572–1.002) | 0.738 | 1.069 (0.723–1.582) |

Data are presented as n (%). * $P$ (P value by Bonferroni correction) = 0.010. Genotypic association tests between groups assuming co-dominant, dominant or log-additive genetic models were carried out by univariate logistic regression using SNPstats and odds ratios (OR) with 95% confidence interval (CI) were calculated. Multiple testing correction was performed by the Bonferroni method.

3). In additive model, the genotype frequencies of rs7759938 were significantly different between patients and controls ($P=0.033$, OR 0.741, 95%CI 0.562–0.977, Table 3). No significant difference was observed between controls and resolver in rs7759938 genotype and allele frequencies (Table 3).

Haplotype frequencies in patients with chronic HBV infection, HBV infection resolvers and healthy controls

The four SNPs of the LIN28B gene constitute 12 haplotypes. The 4 haplotypes with a frequency greater than 0.03 were analyzed. The results show that the 4 haplotype frequencies between patients with chronic HBV infection, HBV infection resolvers and healthy controls had no significant difference but patients had a tendency of lower frequency of rs314277-rs314280-rs369065-rs7759938 haplotype C-A-C-C than resolver ($P=0.053$) or controls ($P=0.069$, Table S7).

Associations between LIN28B polymorphisms and different clinical diseases

LIN28B rs369065 genotype TC frequency was significantly different between patients with different clinical disease, with chronic hepatitis patients having lower frequency than asymptomatic carriers, cirrhosis and HCC ($P=0.019$, Table 4) but with no significant difference in allele frequencies. No significant differences were observed between the genotype and allele frequencies of rs314277, rs314280 and rs7759938 in patients with different clinical diseases (Table 4).

Discussion

LIN28 not only plays key roles in multiple cellular developmental processes, but also is involved in tissue inflammatory response and tumourigenesis. In the present study, we evaluated the associations between LIN28B polymorphisms rs314277, rs314280, rs369065, and rs7759938 and chronic HBV infection in Chinese Han patients. We found that LIN28B rs314280 genotypes GA + AA and allele A and rs7759938 genotypes TC + CC and allele C were associated with a significantly decreased susceptibility of chronic HBV infection. In relation to clinical diseases, chronic hepatitis patients had lower frequency of rs369065 genotype TC than asymptomatic carriers, cirrhosis and HCC but no significant differences were observed in the genotype and allele frequencies of rs314277, rs314280 and rs7759938 between patients with different clinical diseases.
Rs314277 is an intronic polymorphism located in intron 2 of the LIN28B gene [27]. This polymorphism was shown to be associated with recurrence of colorectal cancer in Stage II disease [25]. However, in epithelial ovarian cancer, rs314277 was found to have no significant association with LIN28B levels or patient survival [28]. Correspondingly, we did not find any association between rs314277 polymorphism and the susceptibility of chronic HBV infection or the clinical diseases associated with HBV infection. It is suggested that the effect of rs314277 polymorphism may be disease-specific.

The rs314280 is located at the 5′ end of the LIN28B gene [27]. A previous study revealed that carriage of LIN28B rs314280 genotypes AG and AA/AG may increase the risk of grade ≥3 radiation-induced pneumonitis in patients with non-small cell lung cancer (NSCLC) [29]. We showed that LIN28B rs314280 genotypes GA + AA and allele A were associated with a significantly decreased susceptibility of chronic HBV infection. It is suggested that rs314280 polymorphism may have functional relevance and differentially affect the susceptibility to radiation-induced pneumonitis in NSCLC and chronic HBV infection.

LIN28B rs369065 was shown to be involved in the precocious puberty in Korean girls [30] although its function remains to be examined. The present study found that chronic hepatitis patients had lower frequency of rs369065 genotype TC than asymptomatic carriers, cirrhosis and HCC. This result implies the possibility that rs369065 may potentially influence liver inflammation in chronic HBV infection. However, the real association of rs369065 with chronic HBV infection and HBV-related

| Table 4 Genotype and allele frequencies of LIN28B rs314277, rs314280, rs369065 and rs7759938 in patients with different clinical diseases |
|-------------------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Genotype                                         | AC (n = 91)       | CH (n = 128)      | LC (n = 127)      | HCC (n = 169)     |
| rs314277                                         | **Genotype**      |                   |                   |                   |
| CC                                               | 84 (92.3)         | 124 (96.9)        | 117 (92.1)        | 159 (94.1)        |
| AC                                               | 7 (7.7)           | 4 (3.1)           | 10 (7.9)          | 10 (5.9)          |
| AA                                               | 0 (0)             | 0 (0)             | 0 (0)             | 0 (0)             |
| Allele                                           |                   |                   |                   |                   |
| C                                                | 175 (96.2)        | 252 (98.4)        | 244 (96.1)        | 328 (97.0)        |
| A                                                | 7 (3.8)           | 4 (1.6)           | 10 (3.9)          | 10 (3.0)          |
| rs314280                                         | **Genotype**      |                   |                   |                   |
| GG                                               | 51 (56.0)         | 86 (67.2)         | 74 (58.3)         | 102 (60.4)        |
| GA                                               | 34 (37.4)         | 33 (25.8)         | 45 (35.4)         | 58 (34.3)         |
| AA                                               | 6 (6.6)           | 9 (7.0)           | 8 (6.3)           | 9 (5.3)           |
| Allele                                           |                   |                   |                   |                   |
| G                                                | 136 (74.7)        | 205 (80.1)        | 193 (76.0)        | 262 (77.5)        |
| A                                                | 46 (25.3)         | 51 (19.9)         | 61 (24.0)         | 76 (22.5)         |
| rs369065                                         | **Genotype**      |                   |                   |                   |
| TT                                               | 40 (44.0)         | 70 (54.7)         | 50 (39.4)         | 79 (46.7)         |
| TC                                               | 37 (40.7)         | 37 (28.9)         | 62 (48.8)         | 74 (43.8)         |
| CC                                               | 14 (15.4)         | 21 (16.4)         | 15 (11.8)         | 16 (9.5)          |
| Allele                                           |                   |                   |                   |                   |
| T                                                | 117 (64.3)        | 177 (69.1)        | 162 (63.8)        | 232 (68.6)        |
| C                                                | 65 (35.7)         | 79 (30.9)         | 92 (36.2)         | 106 (31.4)        |
| rs7759938                                        | **Genotype**      |                   |                   |                   |
| TT                                               | 53 (58.2)         | 88 (68.8)         | 72 (56.7)         | 104 (61.5)        |
| TC                                               | 31 (37.1)         | 32 (25.0)         | 46 (36.2)         | 57 (33.7)         |
| CC                                               | 7 (7.7)           | 8 (6.3)           | 9 (7.1)           | 8 (4.7)           |
| Allele                                           |                   |                   |                   |                   |
| T                                                | 137 (75.3)        | 208 (81.2)        | 190 (74.8)        | 265 (78.4)        |
| C                                                | 45 (24.7)         | 48 (18.8)         | 64 (25.2)         | 73 (21.6)         |

AC chronic asymptomatic carrier, CH chronic hepatitis, LC liver cirrhosis, HCC hepatocellular carcinoma. Data are presented as n (%). Genotype frequencies were estimated using the direct counting method. Chi-square test was used for analysis.
Previous studies showed that LIN28B rs7759938 was associated with neither breast cancer risk in European-American women [31] nor the severity of coronary lesions in a Chinese Han population [32]. Rs7759938 was indicated to have borderline significance in influencing LIN28B levels although it was not significantly associated with the survival of patients with epithelial ovarian cancer [28]. In the present study, we found that rs7759938 was associated with susceptibility of chronic HBV infection but it was not associated with the clinical diseases including HBV-related HCC. It is suggested that rs7759938 may have potential predisposing effect on chronic HBV infection but not disease progression related to HBV infection including HCC development.

LIN28B was shown to be involved in the post-transcriptional regulation of HBV replication [17]. The present study showed that LIN28B rs314280 and rs7759938 polymorphisms were associated with the susceptibility of chronic HBV infection. These results may support the role of LIN28B in regulation of HBV replication and infection. Studies have showed that LIN28B plays a key role in regulating inflammation by influencing IL-6 expression [5]. This study found that chronic hepatitis patients had lower frequency of rs369065 genotype TC than asymptomatic carriers, cirrhosis and HCC. This finding may imply the role of LIN28B in the hepatic inflammation of chronic HBV infection. Furthermore, LIN28B plays important roles in regulating cell proliferation and apoptosis and LIN28B is considered to act as an oncogene [10]. LIN28B is involved in an epigenetic switch that links inflammation to cell transformation [5], HBx-induced hepatocarcinogenesis [18–21], HCC development and progression [10, 18, 22, 23] and the prognosis of HCC patients [22]. However, this study did not find any relationship between the polymorphisms genotyped and the development of HBV-related HCC. It should be noted that the sample size of HCC patients in this study is relatively small. This study only genotyped 4 polymorphisms of LIN28B in Han Chinese patients and the potential effect of other polymorphisms on HCC development can not be excluded. Therefore, additional studies are required to genotype more polymorphisms in larger sample sizes of patient populations to clarify the relationship between LIN28B polymorphisms and HBV-related diseases including HCC.

Notably, polymorphisms in LIN28B may influence human growth and development. For example, LIN28B rs314277 has sex-specific effects on growth [33] and significantly associates with age at menarche in Asians [34] and European women [27] and may contribute to idiopathic central precocious puberty susceptibility in Chinese girls [35]. LIN28B rs369065 is associated with precocious puberty in Korean girls [30]. LIN28B rs7759938 is considered a pubertal timing-associated marker associated with age at thelarche and age at menarche [36], pubertal growth [37], prepubertal growth in females and final height in males [33], and adult height in both sexes [38, 39]. The rs7759938 also associates with idiopathic central precocious puberty risk in Chinese girls [35] and earlier age at menarche in women with polycystic ovarian syndrome [40]. Interestingly, in males with chronic HBV infection, earlier-onset puberty is shown to be associated with earlier HBeAg seroconversion, higher serum alanine aminotransferase levels, and a greater HBV viral load reduction [41]. Therefore, the LIN28B polymorphisms may potentially tag the roles of LIN28B gene in influencing the disease course of chronic HBV infection. Particularly, LIN28B rs7759938 has been revealed to be associated with serum testosterone levels and the genotypes related to higher LIN28B expression also associate with lower serum testosterone levels in adult humans [42]. The contribution of LIN28B to the regulation of sex hormone pathways might relate to many of the phenotypes linked to the gene in the human studies [42]. In terms of HBV infection, pathways related to androgen signaling may influence the risk of HBV-related HCC among men [43] and higher levels of androgen signaling, exhibited by higher testosterone levels, may be associated with an increased risk of HBV-related HCC in men [43–45]. Although the present study did not display any association of the polymorphisms genotyped with the development of HBV-related HCC, the effect of LIN28B polymorphisms on sex hormone pathways and the link with HBV-related HCC are interesting issues to be elucidated.

This study has several limitations. First, the sample sizes of patient and control populations included in the study are small and this may lead to bias in the analysis. Second, the study only genotyped 4 polymorphisms with minor allele frequency > 0.03 and $r^2 > 0.8$ in the dbSNP database and Hapmap database of NCBI and there are other polymorphisms which may be relevant remain ungenotyped and this may miss some potentially significant polymorphisms. Third, this study included only Chinese Han population and there may be ethnic deviations in the polymorphisms. Fourth, no functional investigation concerning the polymorphisms was carried out and this may compromise the confidence of the findings. Therefore, further studies are definitely required to extend the studies between LIN28B polymorphisms and HBV-related diseases, especially HCC.
Conclusions
This study showed that LIN28B rs314280 and rs7759938 polymorphisms may be associated with the susceptibility of chronic HBV infection in Han Chinese individuals. Further functional researches and multiple-center studies with large-scale samples are warranted to confirm and extend our findings. In particular, additional studies are needed to investigate more polymorphisms in larger sample sizes of patient populations with different ethnic origin to clarify the association between LIN28B polymorphisms and HBV-related diseases including HCC.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12985-020-01353-7.

Additional file 1 Table S1. Sequences of the probes and primers used for LIN28 rs314277, rs314280, rs369065 and rs7759938 genotyping.

Additional file 2 Table S2. Hardy-Weinberg equilibrium of LIN28B rs314277, rs314280, rs369065 and rs7759938 genotypes.

Additional file 3 Table S3. Genotype frequencies of LIN28B rs314277, rs314280, rs369065 and rs7759938 in patients with chronic HBV infection, infection resolvers and healthy controls.

Additional file 4 Table S4. Allele frequencies of LIN28B rs314277, rs314280, rs369065 and rs7759938 in patients with chronic HBV infection, infection resolvers and healthy controls.

Additional file 5 Table S5. LIN28B rs314277 genotype and allele frequencies in patients with chronic HBV infection, HBV infection resolvers and healthy controls.

Additional file 6 Table S6. LIN28B rs369065 genotype and allele frequencies in patients with chronic HBV infection, HBV infection resolvers and healthy controls.

Additional file 7 Table S7. Haplotypes with a frequency greater than 0.03 in patients with chronic HBV infection, HBV infection resolvers and healthy controls.

Abbreviations
HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HBx: Hepatitis B virus X protein; miRNAs: microRNAs; NSCLC: Non-small cell lung cancer

Acknowledgements
Not applicable.

Authors’ contributions
Conception and design: Qunying Han, Yi Lv and Zhengwen Liu. Acquisition of data: Qunying Han, Jiao Sang, Na Li and Zhengwen Liu. Analysis and interpretation of data: Jiao Sang, Xiaoge Zhang, Na Li and Zhengwen Liu. Writing, review, and/or revision of the manuscript: Qunying Han, Yi Lv and Zhengwen Liu. All the author(s) read and approved the final manuscript.

Funding
This study was supported by National Natural Science Foundation of China (Grant no. 81371798). The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The data sets generated and analyzed during this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All procedures involving human participants were approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University. The study was performed in accordance with Helsinki Declaration. All subjects signed informed consent and volunteered to participate in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Infectious Diseases, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, People’s Republic of China. 2Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China. 3Institute of Advanced Surgical Technology and Engineering, Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an 710061, Shaanxi Province, People’s Republic of China.

Received: 7 April 2020 Accepted: 11 June 2020

Published online: 22 June 2020

References
1. Moss EG, Lee RC, Ambros V. The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell. 1997;88(5):637–46.
2. Shyh-Chang N, Daley GQ. Lin28: primal regulator of growth and metabolism in stem cells. Cell. Stem Cell. 2013;12(4):395–406.
3. Zhou J, Ng SB, Chng WJ. LIN28/LIN28B: an emerging oncogenic driver in cancer stem cells. Int J Biochem Cell Biol. 2013;45(5):973–8.
4. Zhu H, Shyh-Chang N, Segré AV, Shinoda G, Shah SP, Einhorn WS, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147(1):81–94.
5. Ilipooulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139(4):693–706.
6. Ilipooulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39(4):493–506.
7. Mayer F, Schütz A, Döge N, Heinemann U. The Lin28 cold-shock domain remodels pre-let-7 microRNA. Nucleic Acids Res. 2012;40(15):7492–506.
8. Narn Y, Chen C, Gregory RI, Chou JJ, Sliz P. Molecular basis for interaction of let-7 microRNAs with Lin28. Cell. 2011;147(5):1080–91.
9. Piskounova E, Polyarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell. 2011;147(5):1066–79.
10. Guo Y, Chen Y, Ito H, Watanabe A, Ge X, Kodama T, et al. Identification and characterization of Lin-28 homolog B (Lin28b) in human hepatocellular carcinoma. Gene. 2006;354:41–6.
11. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toftanin S, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41(7):843–8.
12. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One. 2010;5(8):e12445.
13. King CE, Wang L, Winograd R, Madison BB, Mongoo PS, Johnstone CN, et al. LIN28 fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene. 2011;30(40):4185–93.
14. Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, et al. Lin28A and Lin28B expression promotes colon cancer progression and metastasis. Cancer Res. 2011;71(12):4260–6.
15. Deng W, Zhang X, Ma Z, Lin Y, Lu M. MicroRNA-125b-5p mediates post-transcriptional regulation of hepatitis B virus replication via the LIN28B/let-7 axis. RNA Biol. 2017;14(10):1389–98.
Sulem P, Gudbjartsson DF, Rafnar T, Holm H, Olafsdottir EJ, Olafsdottir GH, et al. Virology Journal 2010;39: Perry JR, Stolk L, Franceschini N, Lunetta KL, Zhai G, McArdle PF, et al. Meta-analysis of genome-wide association data identifies two loci influencing age at menarche in women with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2012;25(5–6):459–66.

Wu JF, Tsai WP, Hsu HY, Ni YH, Chen HL, Tseui DJ, et al. Effect of puberty onset on spontaneous hepatitis B virus e antigen seroconversion in men. Gastroenterology. 2010;138(3):942–8.e1.

Leinonen JT, Chen YC, Pennonen J, Lehtonen L, Junna N, Tukkainen T, et al. LIN28B affects gene expression at the hypothalamic-pituitary axis and serum testosterone levels. Sci Rep. 2019;9(1):18060.

Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst. 2001;93(21):1644–51.

Yu MW, Cheng SW, Lin MW, Yang YF, Liaw YF, Chang HC, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2000;92(24):2023–8.

Yuan JM, Ross RK, Stanczyk FZ, Govindarajan S, Gao YT, Henderson BE, et al. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai. China Int J Cancer. 1995;63(4):491–3.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.